ATE325621T1 - Il-12 als adjuvanz für bordetella pertussis impfstoffe - Google Patents

Il-12 als adjuvanz für bordetella pertussis impfstoffe

Info

Publication number
ATE325621T1
ATE325621T1 AT97932137T AT97932137T ATE325621T1 AT E325621 T1 ATE325621 T1 AT E325621T1 AT 97932137 T AT97932137 T AT 97932137T AT 97932137 T AT97932137 T AT 97932137T AT E325621 T1 ATE325621 T1 AT E325621T1
Authority
AT
Austria
Prior art keywords
adjuvance
bordetella pertussis
pertussis vaccines
vaccines
bordetella
Prior art date
Application number
AT97932137T
Other languages
English (en)
Inventor
Kingston H G Mills
Bernard P Mahon
Mark S Ryan
Fiona Griffin
Original Assignee
Nat Univ Ireland Maynooth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Ireland Maynooth filed Critical Nat Univ Ireland Maynooth
Application granted granted Critical
Publication of ATE325621T1 publication Critical patent/ATE325621T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97932137T 1996-05-31 1997-05-30 Il-12 als adjuvanz für bordetella pertussis impfstoffe ATE325621T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1587196P 1996-05-31 1996-05-31
US82986597A 1997-03-31 1997-03-31

Publications (1)

Publication Number Publication Date
ATE325621T1 true ATE325621T1 (de) 2006-06-15

Family

ID=26687907

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97932137T ATE325621T1 (de) 1996-05-31 1997-05-30 Il-12 als adjuvanz für bordetella pertussis impfstoffe

Country Status (10)

Country Link
US (5) US6929794B1 (de)
EP (2) EP1649868A1 (de)
JP (2) JP3737519B2 (de)
AT (1) ATE325621T1 (de)
AU (1) AU724743B2 (de)
DE (1) DE69735856T2 (de)
DK (1) DK1015026T3 (de)
ES (1) ES2262181T3 (de)
PT (1) PT1015026E (de)
WO (1) WO1997045139A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE325621T1 (de) * 1996-05-31 2006-06-15 Nat Univ Ireland Maynooth Il-12 als adjuvanz für bordetella pertussis impfstoffe
WO1999040936A2 (en) * 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
AU747917B2 (en) * 1998-03-05 2002-05-30 Medical College Of Ohio, The Enhancement of immunity by intranasal inoculation of IL-12
US6303114B1 (en) * 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
JP4974414B2 (ja) * 1999-05-13 2012-07-11 ワイス・ホールディングズ・コーポレイション アジュバント混合製剤
AUPQ761200A0 (en) 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
IL153133A0 (en) * 2000-06-22 2003-06-24 American Cyanamid Co Qs-21 and il-12 as an adjuvant combination
WO2002038177A2 (en) * 2000-11-10 2002-05-16 Wyeth Holdings Corporation Adjuvant combination formulations
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
CN103561763A (zh) * 2011-02-04 2014-02-05 佐蒂斯有限责任公司 免疫原性支气管炎博德特氏菌组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
CA1340373C (en) * 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
US4705686A (en) * 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
JPH01193231A (ja) * 1988-01-27 1989-08-03 Takeda Chem Ind Ltd 抗腫瘍剤
ATE140483T1 (de) 1988-11-10 1996-08-15 Genetics Inst Natürlicher killerzellen-stimulationsfaktor
US5162223A (en) * 1989-02-17 1992-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Resources Hybridomas and resulting monoclonal antibodies directed against antigens of Bordetella pertussis
ATE121629T1 (de) * 1989-07-14 1995-05-15 Praxis Biolog Inc Stabile interleukine enthaltende impfstoffzusammensetzungen.
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
JPH07508988A (ja) 1992-07-13 1995-10-05 ベイラー・カレッジ・オブ・メディシン 体細胞遺伝子治療の関節への標的化
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
GB2303855B (en) 1994-07-01 1998-10-28 Rican Limited Helicobacter pylori antigenic protein preparation and immunoassays
WO1996010423A1 (en) 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research COMPOSITIONS CONTAINING A p53 DERIVED PROTEIN OR PEPTIDE, AN ADJUVANT, AND INTERLEUKIN-12 AND USES THEREOF
ATE322289T1 (de) * 1994-10-05 2006-04-15 Univ Vanderbilt Interleukin-12 als adjuvans für paramyoxviridae impfstoffe
WO1997000321A1 (en) 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
ATE325621T1 (de) * 1996-05-31 2006-06-15 Nat Univ Ireland Maynooth Il-12 als adjuvanz für bordetella pertussis impfstoffe

Also Published As

Publication number Publication date
JP2005112865A (ja) 2005-04-28
EP1015026B1 (de) 2006-05-10
DE69735856T2 (de) 2006-11-16
US20060263380A1 (en) 2006-11-23
WO1997045139A3 (en) 1998-02-12
EP1015026A2 (de) 2000-07-05
US20060263379A1 (en) 2006-11-23
DE69735856D1 (de) 2006-06-14
DK1015026T3 (da) 2006-09-11
WO1997045139A2 (en) 1997-12-04
AU3567097A (en) 1998-01-05
US20060257419A1 (en) 2006-11-16
ES2262181T3 (es) 2006-11-16
PT1015026E (pt) 2006-08-31
US20050158276A1 (en) 2005-07-21
JP2001527516A (ja) 2001-12-25
US6929794B1 (en) 2005-08-16
AU724743B2 (en) 2000-09-28
EP1649868A1 (de) 2006-04-26
JP3737519B2 (ja) 2006-01-18

Similar Documents

Publication Publication Date Title
DE69735856D1 (de) Il-12 als adjuvanz für bordetella pertussis impfstoffe
EP0597852A4 (de) Impfstoff gegen die pneumonie bei schweinen und methode ihrer präparation.
ITRM940376A0 (it) Dispositivo di controllo del funzionamento di un condizionatore d'ariae metodo per questo scopo.
ATE349890T1 (de) Adjuvant für transkutane immunisation
NL300400I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
HK1044890A1 (zh) 新的疫苗佐劑和疫苗
DE69930166D1 (de) Verfahren und zusammensetzungen für impfung mit dem pseudomonas aeruginosa v-antigen
NO892997D0 (no) Bordetella pertussis vaksine.
ITAN940011A0 (it) Dispositivo di arresto ammortizzato per serrande o tapparelle
ES2136443T3 (es) Limpieza in situ.
FI914433A0 (fi) Gen som kodar ett 30 kilodaltons yttermembranprotein fraon bordetella pertussis.
ITTO910481A1 (it) Apparecchio e procedimento per la verifica della solidita' di un oggetto.
ITAN940006U3 (it) Dispositivo di arresto ammortizzato per serrande o tapparelle
IT220039Z2 (it) Dispositivo di supporto ammortizato, per avvitatori e simili
IT9047612A0 (it) Dispositivo di ancoraggio di protesi dentarie e suo metodo di installazione.
IT9020880A0 (it) Dispositivo e metodo per la proiezione di diapositive.
HUP9902885A1 (hu) Maláriaellenes vakcinakészítmények

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1015026

Country of ref document: EP

REN Ceased due to non-payment of the annual fee